Firibastat

Firibastat (QGC001) 是一种口服活性的 EC33 前体药物。Firibastat 是一种首创的脑氨基肽酶 A (APA) 抑制剂 (Ki=200 nM)，选择性和特异性地抑制高血压大鼠脑血管紧张素 II 转化为血管紧张素 III，并降低血压。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1300.00

1040.00

- +
10mg

￥2175.00

1740.00

- +
25mg

￥4200.00

3360.00

- +
50mg

￥6475.00

5180.00

- +
100mg

￥9712.00

7770.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx33078
CAS: 648927-86-0
别名: QGC001; RB150
分子式: C8H20N2O6S4
分子量: 368.51
纯度: >98%
溶解度: Water : 41.67 mg/mL (113.08 mM; ultrasonic and warming and heat to 60°C)
储存: Store at -20°C
库存: 现货

Background

Firibastat (QGC001), an orally active brain penetrating prodrug of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats[1][2].

When given orally, Firibastat (0.1-30 mg/kg; p.o.) crosses the gastrointestinal and blood-brain barriers, enters the brain, and generates two active molecules of EC33 which inhibit brain APA activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours in hypertensive rats[2].

[1]. Ferdinand KC, et al. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation. 2019;140(2):138-146.
[2]. Keck M, et al. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions. Curr Hypertens Rep. 2019;21(7):50. Published 2019 May 21.